التفاصيل البيبلوغرافية
| العنوان: |
Losartan/hydrochlorothiazide combination is safe and effective for morning hypertension in Very-Elderly patients. |
| المؤلفون: |
Uchiwa, Hiroki, Kai, Hisashi, Iwamoto, Yoshiko, Anegawa, Takahiro, Kajimoto, Hidemi, Fukuda, Kenji, Imaizumi, Tsutomu, Fukumoto, Yoshihiro, for the MAPPY Study Investigators |
| المصدر: |
Clinical & Experimental Hypertension; 2018, Vol. 40 Issue 3, p267-273, 7p |
| مصطلحات موضوعية: |
HYPERTENSION in old age, HYDROCHLOROTHIAZIDE, LOSARTAN, COMBINATION drug therapy, MEDICATION safety, THERAPEUTICS |
| مستخلص: |
Morning hypertension is an independent risk for cerebrovascular and cardiovascular events. Although the prevalence of morning hypertension increases with age, treatment of morning hypertension has not been established, particularly in Very-Elderly patients. We compared the safety and efficacy of a losartan/hydrochlorothiazide (HCTZ) combination in controlling morning hypertension between Very-Elderly (≥75 years) and Young/Elderly patients (<75 years). This study was a subanalysis of the Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy study, in which patients with morning hypertension (≥135/85 mmHg) received a 50-mg losartan/12.5-mg HCTZ combination tablet (combination therapy) or 100-mg losartan (high-dose therapy) for 3 months. High adherence rates and few adverse effects were observed in Very-Elderly patients receiving combination (n = 32) and high-dose (n = 34) therapies and in Young/Elderly patients receiving combination (n = 69) and high-dose (n = 66) therapies. Baseline morning systolic BP (SBP) was similar in both age groups receiving either therapy. Morning SBP was reduced by 20.2 and 18.1 mmHg with combination therapy and by 7.1 and 9.1 mmHg with high-dose therapy in the Very-Elderly and Young/Elderly patients, respectively. Morning BP target (<135/85 mmHg) was achieved in 40.6% and 55.1% by combination therapy and in 14.7% and 24.2% by high-dose therapy in the Very-Elderly and Young/Elderly patients, respectively. Neither therapy changed renal function and serum potassium in Very-Elderly patients. In conclusion, the losartan/HCTZ combination was safe and effective in controlling morning hypertension in Very-Elderly as well as Young/Elderly patients. In addition, combination therapy was also superior to high-dose therapy for lowering morning SBP in Very-Elderly patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical & Experimental Hypertension is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
